Status:

COMPLETED

Evaluating AI-Gatekeeper Software in Coronary Artery Stenosis Screening: a Multicenter RCT

Lead Sponsor:

INFINITT Healthcare

Collaborating Sponsors:

Korea Medical Device Development Fund

Conditions:

Coronary Artery Disease

Diagnosis

Eligibility:

All Genders

19-80 years

Phase:

NA

Brief Summary

The purpose of this study is to determine the efficacy, safety, and cost-effectiveness of AI-Gatekeeper software to assist clinicians in the diagnosis of coronary artery disease by predicting coronary...

Detailed Description

Coronary artery disease (CAD) is a leading cause of global mortality, accounting for over 50% of heart disease-related deaths. Initial evaluations for CAD typically involve chest X-rays, electrocardio...

Eligibility Criteria

Inclusion

  • A patient with symptoms such as chest pain suggestive of coronary artery disease, who underwent routine evaluations including blood tests, electrocardiogram, chest X-ray, and echocardiography
  • Low to Intermediate risk of pretest probabilities of obstructive CAD
  • Voluntarily agreed to participate in this clinical trial and signed the written consent form

Exclusion

  • Acute chest pain (in patients who have not been ruled out for ACS)
  • Previously diagnosed and treated coronary artery disease (myocardial infarction, PCI, CABG)
  • Patients with a life expectancy of less than 2 years due to conditions other than heart disease
  • Those who have not consented to the protocol
  • Participated in a drug or medical device clinical trial within the last 3 months
  • Pregnant or lactating women
  • Allergic to iodine preparations
  • Serum creatine level greater than 1.5 mg/dL or eGFR less than 30 mL/min
  • Baseline irregular and uncontrolled heart rhythm
  • Heart rate greater than 100 beats/minute
  • Systolic blood pressure of 90 mm Hg or less
  • Contraindications to beta blockers or nitroglycerin
  • Patients with complex congenital heart disease
  • Body mass index greater than or equal to 35

Key Trial Info

Start Date :

March 1 2024

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 28 2025

Estimated Enrollment :

450 Patients enrolled

Trial Details

Trial ID

NCT06178900

Start Date

March 1 2024

End Date

February 28 2025

Last Update

March 24 2025

Active Locations (5)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (5 locations)

1

Soonchunhyang University Bucheon Hospital

Bucheon-si, Gyeonggi-do, South Korea, 16995

2

Seoul National University Bundang Hospital

Seongnam-si, Gyeonggi-do, South Korea, 16995

3

Yongin Severance Hospitall, Yonsei University College of Medicine

Yongin, Gyeonggi-do, South Korea, 16995

4

Catholic Kwandong University International St. Mary's Hospital

Incheon, South Korea